Alkermes plc (ALKS)
Nasdaq · Healthcare · Drug Manufacturers - Specialty & Generic
$42.76+2.42%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $7.2B
- P/E (trailing)
- 112.5
- Forward P/E
- 23.6
- 52-week range
- $27.00 – $55.67
- 52-week change
- +34.89%
- EPS (trailing)
- $0.38
- Analyst rating
- 1.7 Buy
- Next earnings
- Oct 28, 2026
Fiscal year to Dec 2025
- Revenue
- $1.5B (−5.25%)
- Net income
- $242M
- Operating margin
- 17.2%
- Diluted EPS
- $1.43
- Free cash flow
- $480M
From the company’s annual report on SEC EDGAR.
About Alkermes plc
Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and LUMRYZ, an extended-release oral suspension product for the treatment of cataplexy or EDS in pediatric patients. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products.
Headquarters: Dublin, Ireland · 2,050 employees · alkermes.com